State of BCI: 2026 Annual Industry Report
The definitive intelligence briefing on the brain-computer interface industry — covering market size, venture funding, clinical trials, human implant counts, regulatory milestones, and the 2026 outlook. Compiled by bciintel.com from primary sources including ClinicalTrials.gov, FDA databases, and company disclosures.
Executive Summary
2026 marks a critical inflection point for the brain-computer interface industry. For the first time, multiple companies are simultaneously enrolling patients across multiple countries. Neuralink has implanted 21 people across four nations. Synchron has completed its US feasibility trial and is preparing a pivotal study targeting FDA Pre-Market Approval. Precision Neuroscience holds FDA 510(k) clearance and is moving toward chronic implants.
Venture investment has reached record levels — more than $1.6B raised in 2025–2026 YTD — driven by high-profile rounds from Neuralink ($650M), Synchron ($200M), Merge Labs ($252M), and Science Corporation ($230M). The market is bifurcating: clinical-stage invasive BCIs targeting serious medical conditions, and consumer-facing non-invasive neurotechnology for productivity and gaming.
Market Overview
The BCI market encompasses a broad range of technologies: commercial deep brain stimulation (Medtronic, Abbott, Boston Scientific) currently constitutes the largest segment by revenue, driven by established markets in Parkinson's disease and essential tremor. The fastest-growing segments are clinical-stage implantable communication BCIs and non-invasive consumer EEG devices.
Funding Landscape
| Company | Round | Amount | Lead Investor(s) | Date |
|---|---|---|---|---|
| Neuralink | Series E | $650M | Jun 2025 | |
| Merge Labs | Seed | $252M | Jan 2026 | |
| Science Corporation | Series C | $230M | Mar 2026 | |
| Synchron | Series D | $200M | Nov 2025 | |
| Science Corporation | Series B | $103.6M | Mar 2025 |
Clinical Trials
| Sponsor | Study | Device | Enrolled / Target | Phase | Status |
|---|---|---|---|---|---|
| Neuralink | N1 Implant | 21 / 30 | feasibility | RECRUITING | |
| Neuralink | N1 Implant | 3 / 3 | feasibility | RECRUITING | |
| Neuralink | N1 Implant | 7 / 10 | feasibility | RECRUITING | |
| Synchron | Stentrode (next-generation) | 0 / 60 | pivotal | NOT YET RECRUITING | |
| Precision Neuroscience | Layer 7 | 50 / 100 | feasibility | ACTIVE | |
| BrainGate Consortium / Massachusetts General Hospital | Utah Array | 14 / 27 | feasibility | ACTIVE | |
| Paradromics | Connexus Direct | 1 / 2 | feasibility | RECRUITING | |
| University of California San Francisco | High-density ECoG | 4 / 10 | feasibility | RECRUITING |
Device Technology
| Device | Type | Electrodes | FDA Status | Stage |
|---|---|---|---|---|
| N1 Implant (Telepathy) | intracortical | 1,024 | IDE | investigational |
| Blindsight Visual Prosthesis | intracortical | 1,024 | BREAKTHROUGH | investigational |
| Stentrode | endovascular | 16 | BREAKTHROUGH | investigational |
| Connexus Direct Data Interface | intracortical | 1,684 | IDE | investigational |
| Utah Array (NeuroPort Electrode 96) | intracortical | 96 | 510K-CLEARED | investigational |
| MoveAgain BCI System | intracortical | 96 | BREAKTHROUGH | investigational |
| Neuralace | intracortical | 10,000 | NONE | r&d |
| BrainGate Neural Interface System | intracortical | 96 | IDE | investigational |
Company Landscape
Companies with active human trials, FDA approvals, or commercial products. Represent >90% of disclosed BCI investment.
Well-funded companies with FDA IDE applications filed or significant research progress. Expect human trials within 1–3 years.
Consumer-focused or early-stage companies. Non-invasive EEG platforms, emerging modalities, and novel approaches.
2026 Outlook
- ·Synchron pivotal trial enrollment expected to begin (targeting FDA PMA by 2028)
- ·Neuralink PRIME study targeting 30-patient enrollment milestone
- ·Science Corporation CE mark approval for PRIMA retinal implant in Europe (expected mid-2026)
- ·FDA guidance on adaptive neurostimulation — implications for closed-loop BCIs
- ·Neuralink Blindsight visual prosthesis first-in-human implant (announced for 2026)
- ·Paradromics Connect-One first chronic speech restoration BCI implant
- ·Precision Neuroscience first-in-human chronic wireless implant study
- ·ONWARD Medical ARC-BCI expanding enrollment; pivotal trial planning
- ·Neuralink next-gen 3,000-electrode device entering development
- ·Merge Labs first technical demonstrations of ultrasound-based BCI
- ·AI-assisted neural decoding: LLM integration enabling fluent language from sparse signals
- ·Wireless charging and fully implantable BCI systems becoming standard
- ·BCI market projected to cross $3.5B by end of 2026
- ·Non-invasive consumer BCI: new OEM partnerships for EEG-integrated headsets
- ·Potential IPO activity: NeuroPace, Synchron, or Neuralink could pursue public markets
- ·International expansion: UAE, UK, Canada, Australia becoming active BCI trial regions
Methodology
This report is compiled by bciintel.com from primary and secondary sources. Data is refreshed continuously by an autonomous agent that monitors news, regulatory databases, and academic publications. Numbers in this report reflect the state of the industry as of April 2026.
Frequently Asked Questions
What is the BCI market size in 2026?
The global brain-computer interface market was valued at approximately $2.8 billion in 2025 and is estimated at $3.2 billion in 2026. Projections from Grand View Research, MarketsandMarkets, and Global Market Insights put the market at $6–12 billion by 2030, representing a 15–18% CAGR. Key growth drivers include clinical BCI approvals, expanding DBS indications, non-invasive consumer neurotechnology, and increasing VC investment.
How much has the BCI industry raised in venture capital?
The BCI industry raised over $1.6 billion in disclosed VC and institutional funding in 2025–2026 YTD. The largest single round was Neuralink's $650M Series E at a $9 billion valuation in June 2025. Other major rounds include Synchron's $200M Series D (November 2025), Merge Labs's $252M seed (January 2026), and Science Corporation's $230M Series C (March 2026). Total disclosed BCI investment since 2018 exceeds $3 billion.
Which BCI companies are closest to FDA approval?
Synchron is the furthest along the FDA regulatory pathway for a chronically-implanted communication BCI, with its COMMAND early feasibility study completed (6/6 patients meeting primary safety endpoint) and a pivotal trial targeting 2026 enrollment. NeuroPace (RNS System) and Medtronic (DBS) already hold commercial PMA approvals. Precision Neuroscience holds FDA 510(k) clearance for temporary (up to 30 days) implantation. Neuralink has IDE approval and is expanding its PRIME feasibility study to 30 participants before pivotal trial planning.
What are the key BCI milestones expected in 2026?
Key BCI milestones in 2026 — completed and upcoming: Completed: (1) Neuralink Blindsight first-in-human implant (February 2026), marking the first cortical visual prosthesis from a commercial BCI company; (2) Paradromics Connect-One enrollment opened at University of Michigan (February 2026), the first IDE study for high-bandwidth speech restoration; (3) PRIME enrollment reached 28 participants by May 2026 (target: 30). Still ahead in 2026: (4) Synchron's pivotal trial beginning enrollment across 4+ US sites; (5) Precision Neuroscience's first-in-human chronic wireless implant; (6) Science Corporation CE mark approval for PRIMA retinal implant in Europe; (7) Merge Labs' first technical demonstrations of its ultrasound-based BCI.
What is the difference between invasive and non-invasive BCIs?
Invasive BCIs require surgical implantation and include intracortical devices (electrodes penetrate brain tissue, e.g., Neuralink N1, BrainGate Utah Array), endovascular devices (delivered via blood vessel, e.g., Synchron Stentrode), and ECoG devices (placed on brain surface, e.g., Precision Neuroscience Layer 7). Non-invasive BCIs use external sensors — most commonly EEG headsets (EMOTIV EPOC, OpenBCI, Neurable MW75 Neuro) that measure scalp electrical signals. Invasive BCIs achieve significantly higher signal quality and bandwidth but require surgery. Non-invasive BCIs are safe, portable, and commercially available but have lower resolution.